Eli Lilly Partners with Creyon Bio for Accelerated Discovery and Development of RNA-Targeted Oligonucleotides for Various Diseases
Shots:
- Eli Lilly has entered into a global licensing & multi-target research collaboration with Creyon Bio to identify, develop & market novel RNA-targeted oligonucleotide therapies for Lilly’s named targets using Creyon’s AI-powered Oligo Engineering Engine
- As per the deal, Lilly will get exclusive rights of lead candidates & handle further research, development & marketing upon achievement of certain milestones in exchange for $13M upfront in cash & equity, plus ~$1B in development & commercial milestones
- Oligo Engineering Engine accelerates development timelines by using principles of quantum chemistry, while reducing reliance on conventional trial-&-error methods to develop RNA-targeted oligo therapies
Ref: Businesswire | Image: Eli Lilly & Creyon Bio
Related News:- BigHat Biosciences Collaborates with Eli Lilly to Advance AI-Driven Antibody Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
